COVIDRIVE Study #1: COVID-19 vaccine effectiveness (CVE) against hospitalisation

COVIDRIVE’s first study started in September 2021, and by 14th of September 2022 has recruited over 5000 patients across 15 hospitals in 4 European countries.

Study design: multi-country hospital-based case-control study with test-negative case-control design.

  • COVID-19 CVE against COVID-19 hospitalisations (primary and booster vaccination);
  • CVE by genetic variants;
  • CVE by time since last dose (duration of protection);
  • CVE in specific risk groups (immunocompromised, risk conditions, pregnant…)
Study progress

Recruitment started on Sept 15th, 2021 for AstraZeneca and Janssen. Moderna and Novavax started their study in June 2022, Sanofi and Valneva will potentially start in December 2022.

Map of participating hospitals in COVIDRIVE Study 1
Participating hospitals:
  • Recruiting: Spain (7 hospitals), Italy (4 hospitals), Austria (1 hospital), Belgium (3 hospitals)
  • In start-up: France (5 hospitals) and Germany (2 hospitals)
  • In feasibility assessment: Denmark and United Kingdom (database-driven TND study)
Recruitment update (as of 14th September 2022):
  • 5070 SARI (Severe Acute Respiratory Infection) patients recruited
  • 1550 COVID-19 cases identified
Figure: Cumulative number of recruited SARI patients by calendar month